NASDAQ: IMRX

Immuneering Corporation

Healthcare | Biotechnology

No licensed closing price on file for IMRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Immuneering Corporation (NASDAQ: IMRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:34 UTC.

What Immuneering Corporation does

The company is a clinical-stage oncology firm developing Deep Cyclic Inhibitors, a new category of anti-cancer medicines designed to disrupt tumor cell signaling while sparing healthy cells through intermittent dosing rather than continuous inhibition. Its lead product candidate, atebimetinib, is an oral MEK inhibitor currently in development for pancreatic cancer and other solid tumors, with a Phase 3 trial planned to begin enrollment.

Summarized from Immuneering Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-15
Return on equity	-45.98%

Revenue, margins & earnings

Net income
Taxes & interest
Operating expenses
Cost of revenue
Net loss year

Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-07-17

Most recent filed transactions — July 2026:

2026-07-17Chief Financial OfficerStock OptionAward650,000—
2026-06-24PRESIDENT AND CEOPurchase2,400$10.9K
2026-06-16CHIEF SCIENTIFIC OFFICERPurchase6,035$25.0K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC9,704,610$48.43M+1.0%
BlackRock, Inc.4,374,020$21.83M+190.2%
Sanofi2,708,559$13.52M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-06-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-06-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-07-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny
Seeking Alpha Feed2026-10-19
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Seeking Alpha Feed2026-07-27
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Immuneering Corporation do?

When did IMRX last file with the SEC?

Immuneering Corporation's most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:34 UTC. This page is also available as JSON at /api/data?ticker=IMRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMRX and 5,000+ tickers.

Create a free account — keep IMRX

For your agent

GET /api/data?ticker=IMRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt